Share Email Print

Proceedings Paper

Tissue level material composition and mechanical properties in Brtl/+ mouse model of Osteogenesis Imperfecta after sclerostin antibody treatment
Author(s): William R. Lloyd III; Benjamin P. Sinder; Joseph Salemi; Michael S. Ominsky; Joan C. Marini; Michelle S. Caird; Michael D. Morris; Kenneth M. Kozloff
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Osteogenesis imperfecta (OI) is a genetic disorder resulting in defective collagen or collagen-associated proteins and fragile, brittle bones. To date, therapies to improve OI bone mass, such as bisphosphonates, have increased bone mass in the axial skeleton of OI patients, but have shown limited effects at reducing long bone fragility. Sclerostin antibody (Scl- Ab), currently in clinical trials for osteoporosis, stimulates bone formation and may have the potential to reduce long bone fracture rates in OI patients. Scl-Ab has been investigated as an anabolic therapy for OI in the Brtl/+ mouse model of moderately severe Type IV OI. While Scl-Ab increases long bone mass in the Brtl/+ mouse, it is not known whether material properties and composition changes also occur. Here, we report on the effects of Scl-Ab on wild type and Brtl/+ young (3 week) and adult (6 month) male mice. Scl-Ab was administered over 5 weeks (25mg/kg, 2x/week). Raman microspectroscopy and nanoindentation are used for bone composition and biomechanical bone property measurements in excised bone. Fluorescent labels (calcein and alizarin) at 4 time points over the entire treatment period are used to enable measurements at specific tissue age. Differences between wild type and Brtl/+ groups included variations in the mineral and matrix lattices, particularly the phosphate v1, carbonate v1, and the v(CC) proline and hydroxyproline stretch vibrations. Results of Raman spectroscopy corresponded to nanoindentation findings which indicated that old bone (near midcortex) is stiffer (higher elastic modulus) than new bone. We compare and contrast mineral to matrix and carbonate to phosphate ratios in young and adult mice with and without treatment.

Paper Details

Date Published: 26 February 2015
PDF: 6 pages
Proc. SPIE 9303, Photonic Therapeutics and Diagnostics XI, 93033U (26 February 2015); doi: 10.1117/12.2080261
Show Author Affiliations
William R. Lloyd III, Univ. of Michigan, Ann Arbor (United States)
Benjamin P. Sinder, Univ. of Michigan, Ann Arbor (United States)
Joseph Salemi, Univ. of Michigan, Ann Arbor (United States)
Michael S. Ominsky, Amgen Inc. (United States)
Joan C. Marini, National Institutes of Child Health and Human Development (United States)
Michelle S. Caird, Univ. of Michigan, Ann Arbor (United States)
Michael D. Morris, Univ. of Michigan, Ann Arbor (United States)
Kenneth M. Kozloff, Univ. of Michigan, Ann Arbor (United States)

Published in SPIE Proceedings Vol. 9303:
Photonic Therapeutics and Diagnostics XI
Hyun Wook Kang; Brian J. F. Wong M.D.; Melissa C. Skala; Bernard Choi; Guillermo J. Tearney M.D.; Andreas Mandelis; Nikiforos Kollias; Kenton W. Gregory M.D.; Mark W. Dewhirst D.V.M.; Justus F. Ilgner M.D.; Alfred Nuttal; Haishan Zeng; Laura Marcu; Claus-Peter Richter, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?